Cuál es el precio por MBX Biosciences, Inc. Common Stock (MBX)

Precio por MBX Biosciences, Inc. Common Stock (MBX) es de$67.63

Cuál es la capitalización de mercado por MBX Biosciences, Inc. Common Stock (MBX)

Capitalización de mercado por MBX Biosciences, Inc. Common Stock (MBX) es $3.22B

MBX Biosciences, Inc. Common Stock (MBX) Ratio P/B

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

Año	Ratio P/B	Cambiar
Not enough data for the provided dates.

Año

Ratio P/B

Cambiar

Not enough data for the provided dates.

Empresa	Ratio P/B	Diferencia del ratio P/B	País
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
Moderna, Inc. MRNA.US	3.7087	-	US
CSL Limited CSL.AX	2.5054	-	AU
Lonza Group AG LONN.SW	-	-	CH

Empresa

Ratio P/B

Diferencia del ratio P/B

País